Abbott

Abbott India shares gain after company assures fixing issues at Goa Plant

Abbott on August 18 had intimated the DCGI office regarding voluntary product recall of all batches of Digene Gel of all flavors (Mint, Orange, mix fruits flavor) which are within the self-life and manufactured at Goa facility

Short Call | Inflation a spoilsport; bulletproof fluorochems; Voltas, Abbot, Bata, Vedanta in focus

Kotak cautions investors that India’s relatively strong macro-economic position cannot be taken for granted. Reasons: rising food prices, rising crude oil prices, weak tax collections and inflation likely to stay elevated

How Abbott is bringing together groups to quickly identify viral threats in India, world

When an illness of unknown origin is identified, Abbott’s coalition partners move to sequence samples, identify if it’s a known or unknown pathogen, and when needed, alert health systems or public health agencies about these cases

Telangana drug sleuths to crack down on large counterfeit drug cartels

There are some 30 players in all in the Indian market for hypothyroidism drugs, Abbott India’s Thyronorm leads the market with over 50% share, which is followed by Eltroxin from GSK and Thyrox from Macleods.

Abbott baby formula plant again stops production, this time because of flooding

Abbott Nutrition, which worsened a baby formula shortage in the United States when it temporarily shut down a Michigan plant in February because of the presence of bacteria, said it had again stopped production at the plant, this time because of flooding during a severe storm.

FDA and Abbott reach agreement on baby formula to try to ease shortage

The FDA said it expected Abbott to restart production in about two weeks. The agreement stems from a US Department of Justice complaint and consent decree with the company and three of its executives

Syngene: Heavy investment phase makes it a long-term play

Beyond contract research, another trend to watch for Syngene is the pick-up in contract manufacturing business in biologics and APIs

Abbott launches continuous blood glucose monitoring system FreeStyle Libre in India

The FreeStyle Libre sensor measures glucose every minute in interstitial fluid through a small (5.5mm long) filament that is inserted just under the skin and held in place with a small adhesive pad.

Coronavirus update: Abbott's card-sized 15-minute COVID-19 test gets US FDA nod for emergency use

Abbott will also launch a mobile app NAVICA which will allows people to store, access and display their COVID-19 test results.

Abbott launches quadrivalent vaccine for influenza in India

"We are excited with the launch of the quadrivalent version of our flu vaccine, which can be offered to both children above six months and adults. This particular type of vaccine provides good immune response with less side-effects," Abbott India Medical Director Srirupa Das said.

Unable to buy Limcee Vitamin-C tablets from medical stores? Blame it on China

When Kothari prodded his chemist, he told him that there is shortage of Rs 15 - Limcee pack in the market, and what he is offering is the reformulated version of Limcee, called Limcee Plus.

Abbott takes digital route in India to improve patient health outcomes

“It’s a neutral platform, designed to bridge the communication gap between doctors and consumers,” said Jawed Zia, Head of Abbott’s Pharmaceutical Business in India.

Abbott discontinues selling Xience Alpine stents in India

The National Pharmaceutical Pricing Authority (NPPA) in a meeting on April 23 had approved the change in date of withdrawal of Xience Alpine brand of coronary stents proposed by Abbott Healthcare.

Abbott increases nutrition portfolio for metabolic disorders

Abbott's Nutrition Metabolic Formulas (ANMF) will help infants diagnosed with IEM in India.

Havas Group acquires healthcare agency Sorento

Sorento will partner with 'Havas Health and You' business unit and be rebranded Havas Life Sorento, the agency said in a statement.

Stocks in the news: Tata Steel, Golden Tobacco, Lupin, Capital First, IRB Infra

Under cost pressure, Abbott to urge NPPA to allow withdrawal of stents again

Last week, Indian drug regulator NPPA rejected applications filed by Abbott and Medtronics to withdraw their stent products from market technical grounds.

Indian drug market grows at 9.6% in March on waning demonetisation effect

The Indian pharmaceutical market (IPM) grew at a much better pace in March led by improved sales of drugs in chronic segment and acute segment bucking the trend of a sequential decline. The fading demonetization impact also aided the market growth.

In last 5 years midcaps have outperformed Nifty by 50%; will the rally continue?

In FY17, midcaps have delivered 35 percent positive returns, as against nearly 19 percent by the Nifty.

Stents to get cheaper by as much as 85% as drug body caps price

NPPA capped the prices of bare metal stent at Rs.7260 and drug eluting stent (DES) and biodegradable stents at Rs.29,600. Both the prices were exclusive of value added tax. DES constitutes 95 percent of the market.

Sebi fines Piramal Ent for lapses on insider trade control

The Securities and Exchange Board of India (Sebi) has disposed of charges against the company's director Harinder Sikka saying he cannot be faulted for the transactions as the company had not closed the trading window which would have checked his trades by way of grant of pre-clearances.